Evidence map›Paper›PMID 19533771›Full record

ArticleAmerican journal of medical genetics. Part A2009

Narrowing critical regions and determining penetrance for selected 18q- phenotypes.

Jannine D Cody, Patricia L Heard, Analisa C Crandall, Erika M Carter, John Li, L Jean Hardies, Jack Lancaster, Brian Perry, Robert F Stratton, Courtney Sebold and 6 more

Open access · greenAbstract read
In one paragraph

Article in American journal of medical genetics. Part A, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
9.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Diagnostic yield of exome sequencing in congenital vertical talus.European journal of medical genetics · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Adults with Chromosome 18 Abnormalities.Journal of genetic counseling · 2015
    Article
  18. Article
  19. Article
  20. Sensorineural hearing loss in people with deletions of 18q: hearing in 18q-.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Jannine D CodyDepartment of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA. cody@uthscsa.edu
Patricia L Heard
Analisa C Crandall
Erika M Carter
John Li
L Jean Hardies
Jack Lancaster
Brian Perry
Robert F Stratton
Courtney Sebold
Rebecca L Schaub
Bridgette Soileau
Annice Hill
Minire Hasi
Peter T Fox
Daniel E Hale
The University of Texas Health Science Center at San Antonio · USImaging Center · US

Funding

ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PLISZKA, STEVEN R. · 1985 to 2008
$23.1M
Identification of Dosage Sensitive Genes on 18qR01HD045907 · NICHD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CODY, JANNINE DE MARS · 2004 to 2007
$1.4M
NCRR NIH HHS M01 RR001346NCRR NIH HHS M01-RR-001346NICHD NIH HHS R01 HD045907NICHD NIH HHS R01-HD-045907
6 · The paper itself

Abstract

One of our primary goals is to help families who have a child with an 18q deletion anticipate medical issues in order to optimize their child's medical care. To this end we have narrowed the critical regions for four phenotypic features and determined the penetrance for each of those phenotypes when the critical region for that feature is hemizygous. We completed molecular analysis using oligo-array CGH and clinical assessments on 151 individuals with deletions of 18q and made genotype-phenotype correlations defining or narrowing critical regions. These nested regions, all within 18q22.3 to q23, were for kidney malformations, dysmyelination of the brain, growth hormone stimulation response failure, and aural atresia. The region for dysmyelination and growth hormone stimulation response failure were identical and was narrowed to 1.62 Mb, a region containing five known genes. The region for aural atresia was 2.3 Mb and includes an additional three genes. The region for kidney malformations was 3.21 Mb and includes an additional four genes. Penetrance rates were calculated by comparing the number of individuals hemizygous for a critical region with the phenotype to those without the phenotype. The kidney malformations region was 25% penetrant, the dysmyelination region was 100% penetrant, the growth hormone stimulant response failure region was 90% penetrant with variable expressivity, and the aural atresia region was 78% penetrant. Identification of these critical regions suggest possible candidate genes, while penetrance calculations begin to create a predictive phenotypic description based on genotype.

Indexed as

Chromosome AberrationsChromosome MappingChromosomes, Human, Pair 18PenetranceEar DiseasesEar, MiddleGenetic LinkageGenotypeGrowth DisordersHereditary Central Nervous System Demyelinating DiseasesHumansKidneyKidney DiseasesPhenotype

Identifiers

PMID19533771
PMCPMC5325704
OpenAlexW2123721022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.